Literature DB >> 9769703

Signaling via JAK tyrosine kinases: growth hormone receptor as a model system.

C Carter-Su1, L S Smit.   

Abstract

During the past 4 years, significant progress has been made in elucidating the earliest events following binding of ligands to members of the cytokine receptor superfamily. This is a rapidly growing family of receptors that currently includes receptors for growth hormone (GH); prolactin; erythropoeitin; granulocyte colony-stimulating factor; granulocyte macrophage colony-stimulating factor; interleukin(IL)s 2-7, 9-13, 15; interferon (IFN)-alpha, beta, and gamma; thrombopoietin; leptin; oncostatin M; leukemia inhibitory factor (LIF); ciliary neurotrophic factor; and cardiotropin-1. Despite their diverse physiological effects in the body, ligands that bind to members of this family share multiple signaling pathways. An early and most likely initiating event for all of them is the activation of one or more members of the Janus (or JAK) family of tyrosine kinases. The activated JAK kinases, which form a complex with the cytokine receptor subunits, phosphorylate themselves as well as the receptor. These phosphorylated tyrosines form binding sites for various signaling molecules that are themselves thought to be phosphorylated by JAK kinases, including 1) signal transducers and activators of transcription (Stats), which regulate transcription; 2) She proteins that recruit Grb2-SOS complexes, thereby initiating the Ras-MAP kinase pathway; and 3) insulin receptor substrate (IRS) proteins that are thought to regulate metabolic events in the cell. Additional other signaling molecules have been implicated in signaling by some cytokines, including protein kinase C, SH2-B beta, and intracellular Ca. This review uses the GH receptor as a model system for studying cytokine signaling and summarizes some of the data used to establish JAK2 as a GH receptor-associated tyrosine kinase and to identify signaling molecules that lie downstream of JAK2. Since these pathways are shared by multiple cytokines, this review also discusses factors that might contribute to specificity of response to different cytokines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9769703

Source DB:  PubMed          Journal:  Recent Prog Horm Res        ISSN: 0079-9963


  17 in total

1.  Identification of SH2B2beta as an inhibitor for SH2B1- and SH2B2alpha-promoted Janus kinase-2 activation and insulin signaling.

Authors:  Minghua Li; Zhiqin Li; David L Morris; Liangyou Rui
Journal:  Endocrinology       Date:  2007-01-04       Impact factor: 4.736

2.  Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.

Authors:  Gang Wang; Jia-Hui Chen; Yong Qiang; Dong-Zhi Wang; Zhong Chen
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

3.  Stimulation of pancreatic beta-cell proliferation by growth hormone is glucose-dependent: signal transduction via janus kinase 2 (JAK2)/signal transducer and activator of transcription 5 (STAT5) with no crosstalk to insulin receptor substrate-mediated mitogenic signalling.

Authors:  S P Cousin; S R Hügl; M G Myers; M F White; A Reifel-Miller; C J Rhodes
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

4.  Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter.

Authors:  C J Auernhammer; C Bousquet; S Melmed
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

Review 5.  The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.

Authors:  Martha Wadleigh; D Gary Gilliland
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

6.  Gamma interferon and lipopolysaccharide interact at the level of transcription to induce tumor necrosis factor alpha expression.

Authors:  J Y Lee; K E Sullivan
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

7.  Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5.

Authors:  N A Sims; P Clément-Lacroix; F Da Ponte; Y Bouali; N Binart; R Moriggl; V Goffin; K Coschigano; M Gaillard-Kelly; J Kopchick; R Baron; P A Kelly
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

Review 8.  Skeletal effects of growth hormone and insulin-like growth factor-I therapy.

Authors:  Richard C Lindsey; Subburaman Mohan
Journal:  Mol Cell Endocrinol       Date:  2015-09-25       Impact factor: 4.102

9.  Role of the GH/IGF-I axis in the growth retardation of weaver mice.

Authors:  Weiguo Yao; Kathleen Bethin; Xianlin Yang; Jin Zhong; Wei-Hua Lee
Journal:  Endocrine       Date:  2007-11-27       Impact factor: 3.633

Review 10.  Nanomedicines in the treatment of acromegaly: focus on pegvisomant.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes Romijn
Journal:  Int J Nanomedicine       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.